UCB stock pre-market at EUR 206.55 on October 16, 2026
Published on 10/16/2026 at 07:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSDates and valuation ahead
- UCB lists STACCATO alprazolam topline results for Q4 2026 or H1 2027.
- UCB stock trades pre-market at EUR 206.55 at 7:41 a.m. CEST at Lang & Schwarz on October 16, 2026.
- MarketWatch lists a P/E ratio of 17.87 and a dividend yield of 0.50 percent on October 14, 2026.
At 7:41 a.m. CEST on October 16, 2026, UCB stock was quoted at EUR 206.55 in pre-market trading at Lang & Schwarz. The bid was EUR 205.80 and the ask was EUR 207.30.
Pre-market indication
Lang & Schwarz showed UCB at EUR 206.55 on October 16, 2026, at 7:41 a.m. CEST, before the Xetra session. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of UCB stock.
What matters today
UCB's investor-relations materials list topline results for STACCATO alprazolam in Q4 2026 or H1 2027, as shown on the UCB investor-relations website. MarketWatch records a 52-week low of EUR 197.45 and a 52-week high of EUR 289.50; the low is 4.41 percent below the Lang & Schwarz price. MarketWatch lists a P/E ratio of 17.87 and a dividend yield of 0.50 percent in its October 14, 2026 quote data.
Pipeline and portfolio
UCB's investor-relations materials report BIMZELX sales of EUR 1.52 billion in the first half of 2026 and peak-sales guidance above EUR 7 billion. The same materials report first-half 2026 sales of EUR 954 million for CIMZIA and EUR 327 million for BRIVIACT.
Market context: Market report Euro Stoxx 50.
